Publications & Reports Print

DSC_0033

BBMRI Documents

BBMRI documents shall as far as possible to be open to public. To access these documents go to BBMRI Intranet - and click on Public Documents. No login required.
Draft documents will be available on the website in member area only.
To acknowledge BBMRI in grant applications please indicate its full title, acronym
(Biobanking and Biomolecular Resources Research Infrastructure, BBMRI) and Grant Agreement Number 212111.

 

Reports

Final Report

Dissemination levels: PU = Public, PP = Restricted to participants, including the Commission Services

Please note that the report is currently under evaluation by the Commission Services.

 

BBMRI Final Report - PU


BBMRI 2nd Periodic Report (complete) - PP

BBMRI 2nd Periodic Report (summary) - PU

Annexes:

Annex 1: Final Report from WP2 (WP2) - PU

Annex 2: Inventory on existing clinical biobanks (WP3) - PP

Annex 3: Concept for national hubs of clinical biobanks (WP3) - PP

Annex 4: Final Report from WP3 (WP3) - PU

Annex 5: IMI-Training in medicines research (WP3) - PP

Annex 6: Report on European affinity reagent resources and centres with inventories and details of access and prospective plans (WP4) - PU

Annex 7: Report on European technology resources for nucleic acids, proteins and metabolites and prospective plans (WP4)- PP

Annex 8: Report on quality standards to be adopted for reagents in Europe (WP4) - PP

Annex 9: Reagent database with common ontology standards (WP4) - PU

Annex 10: Technologies database (WP4) - PU

Annex 11: Final Report from WP4 (WP4) - PU

Annex 12: Strategy for unique and secure identities for specimens, subjects and biobanks (WP5) - PP

Annex 13: Strategy for communication between biobanks including a common nomenclature, compatible software techniques and appropriate information transmission policies (WP5) - PP

Annex 14: Requirements for a general information management system for European biobanks (WP5) - PU

Annex 15: Strategy for a federated hub and spoke structure for European Biobanking (WP5) - PP

Annex 16: Final Report from WP5 (WP5) - PU

Annex 17: Data Protection Standard to govern cross border DP issues that is compliant with the EU Data Protection Directive (WP5 and WP6) - PU

Annex 18: Background document on how BBMRI should address its social dimension (WP6) - PU

Annex 19: European infrastructure for ELSI issues (WP6) - PP

Annex 20: Uploading and validation of documents of BBMRI Members and Partners (WP6) - PU

Annex 21: Flow chart of an operational integrated ELSI governance model (WP6) - PP

Annex 22: Overall report and Recommendations for BBMRI ELSI, including educational proposals (WP6) - PU

Annex 23: Implementation and monitoring of gender issue plan (WP6) - PP

Annex 24: Final Report from WP6 (WP6) - PU

Annex 25: Contracts ready for signature (MoU) (WP7) - PU

Annex 26: Final Report from WP7 (WP7) - PU

Annex 27: Operational concept (BBMRI Business Plan) (WP1) - PP

Annex 28: Definition of legal entity of BBMRI (BBMRI Statutes) (WP1) - PU

Annex 29: Contracts for BBMRI Partners (Partner Charta) (WP1) - PU

Annex 30: Global status and consensus report (WP1) - PU

Annex 31: Final Report from WP1 (WP1) - PU

 

 

 

 

Scientific Papers

Bourbeillon et al., (2010) Minimum Information about a Protein Affinity Reagent (MIAPAR)”, Nature Biotechnology.28: 650-653)

Chadwick R, Strange H, (2009) Harmonisation and standardisation in ethics and governance:

conceptual and practical changes IN Widdows H, Mullen C(eds.) The Governance of Genetic Information: Who Decides? Cambridge University Press. Abstract

Gottweis H, Lauss G (2010), Biobank governance in the post-genomic age, Personalized Medicine. Vol 7. No. 2, p 187-195. Abstract

Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N, Falus A, Melegh B. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples:relationship to worldwide allelic frequencies. Blood Cells Mol Dis 2009;43(3):239-42.

Sipeky C, Csongei V, Jaromi L, Safrany E, Polgar N, Lakner L, Szabo M, Takacs I, Melegh B. 81):671-5.

Vitamin K epoxide reductase complex 1(VKORC1) haplotypes in healthy Hungarian and Roma population samples. Pharmacogenomics 2009;10(6):1025-32.

Kisfali P, Mohás M, Maász A, Polgár N, Hadarits F, Markó L, Brasnyó P, Horvatovich K, Oroszlán T, Bagosi Z, Bujtor Z, Gasztonyi B, Rinfel J, Wittmann I, Melegh B. Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009 Aug 17.

Polgár N, Járomi L, Csöngei V, Maász A, Sipeky C, Sáfrány E, Szabó M, Melegh B. Triglyceride level modifying functional variants of GALTN2 and MLXIPL in patients with ischaemic stroke. Eur J Neurol. 2010 Feb. 10

Sipeky C, Csongei V, Jaromi L, Safrany E, Maasz A, Szabo M, Takacs I, Beres J, Melegh B.Genetic variability of MDR1 (ABCB1) C1236T, G2677T/A and C3435T polymorphisms and natural haplotype profile in Roma and Hungarian populations with a review of the literature. Pharmacogenomics. (Submitted)

Nelis M, Esko T, et al., Genetic structure of Europeans: a view from the North-East. PLoS One. 2009;4(5):e5472. Epub 2009 May

Walters RG, et al., A new highly penetrant form of obesity due to deletions on chromosome 16. p. 11.2. Nature. 2010 Feb 4;463. 72. Abstract

Yuille M. van Ommen GJ, Bréchot Ch, Cambon-Thomsen A, Dagher G, Landegren U, Litton J-E, Pasterk M, Peltonen L, Taussig M, Wichmann E., Zatloukal, K. Biobanking for Europe. Brief Bioinform 2008;9,1:14-24


 

 
 
sikis sesli sohbet